NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|221041544|dbj|BAH12449|]
View 

unnamed protein product [Homo sapiens]

Protein Classification

M1 family metallopeptidase( domain architecture ID 10176184)

M1 family metallopeptidase containing an ERAP1-like C-terminal domain with HEAT-like repeats; similar to aminopeptidase N, a broad specificity aminopeptidase, and glutamyl aminopeptidase, which releases N-terminal glutamate from a peptide

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
17-419 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


:

Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 608.04  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  17 INYSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASYAPEGDEEIHATGFNYQNEDEKVTLSFPSTLQTG 96
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETEFLTITLDETLPPG 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  97 T-GTLKIDFVGELNDKMKGFYRSKYTTPSGEVRYAAVTQFE----------------------------------NVIDR 141
Cdd:cd09601   81 EnYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEptdarrafpcfdepafkatfditithpkgytalsNMPPV 160
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 142 KPYPDDENLVEVKFARTPVMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYP 221
Cdd:cd09601  161 ESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIPYP 240
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 222 LPKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWI 301
Cdd:cd09601  241 LPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFATYM 320
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 302 EYLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGM 381
Cdd:cd09601  321 EYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVFRKGL 400
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|..
gi 221041544 382 NMYLTKFQQKNAATEDLWESLENASG----KPIAAVMNTWTK 419
Cdd:cd09601  401 RKYLKKHAYGNATTDDLWEALQEASGeskpLDVKEIMDSWTL 442
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
498-811 4.99e-106

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


:

Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 328.85  E-value: 4.99e-106
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  498 WVKLNLGTVGFYRTQYSSAMLESLLPGIRDLSLPPVDRLGLQNDLFSLARAGIISTVEVLKVMEAFVNEPNYTVWSDLSC 577
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLLSKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAALS 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  578 NLGILSTLLSHTDFYEEIQEFVKDVFSPIGERLGWDPKPGEGHLDALLRGLVLGKLGKAGHKATLEEARRRFKDHVEGKQ 657
Cdd:pfam11838  81 QLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEAPPGESHLDRQLRALLLSAACSAGDPECVAEAKKLFDAWLDGDD 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  658 ILSADLRSPVYLTVLKHGDGTTLDIMLKLHKQADMQEEKNRIERVLGATLLPDLIQKVLTFAL-SEEVRPQDTVSVIGGV 736
Cdd:pfam11838 161 AIPPDLRWAVYCAAVANGGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALdSDEVRNQDLRAVIAGL 240
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 221041544  737 AGgSKHGRKAAWKFIKDNWEELYNRYQGGFLISRLIKLSVEGFAVDKMAGEVKAFFESHPAPSAERTIQQCCENI 811
Cdd:pfam11838 241 AS-NPAGRDLAWDFVKENWDALVKRLGGGSSLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRRALAQALETI 314
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
17-419 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 608.04  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  17 INYSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASYAPEGDEEIHATGFNYQNEDEKVTLSFPSTLQTG 96
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETEFLTITLDETLPPG 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  97 T-GTLKIDFVGELNDKMKGFYRSKYTTPSGEVRYAAVTQFE----------------------------------NVIDR 141
Cdd:cd09601   81 EnYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEptdarrafpcfdepafkatfditithpkgytalsNMPPV 160
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 142 KPYPDDENLVEVKFARTPVMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYP 221
Cdd:cd09601  161 ESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIPYP 240
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 222 LPKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWI 301
Cdd:cd09601  241 LPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFATYM 320
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 302 EYLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGM 381
Cdd:cd09601  321 EYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVFRKGL 400
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|..
gi 221041544 382 NMYLTKFQQKNAATEDLWESLENASG----KPIAAVMNTWTK 419
Cdd:cd09601  401 RKYLKKHAYGNATTDDLWEALQEASGeskpLDVKEIMDSWTL 442
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
200-417 1.84e-124

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 373.16  E-value: 1.84e-124
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  200 FALEVAAKTLPFYKDYFNVPYPLPKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWF 279
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  280 GNLVTMEWWTHLWLNEGFASWIEYLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYS 359
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*....
gi 221041544  360 KGASVIRMLHDYIGDKDFKKGMNMYLTKFQQKNAATEDLWESLENASG-KPIAAVMNTW 417
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGpLDVDSFMDTW 219
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
9-580 8.84e-115

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 362.04  E-value: 8.84e-115
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544   9 RLPADVSPINYSLCLKPDLLDFTFEGKLEAAAQVRQA-TNQIVMNCADIDIITASyapegdeeIHATGFNYQNEDEKVTL 87
Cdd:COG0308   10 YRPPGYDVTHYDLDLDLDPATTRLSGTATITFTATEApLDSLVLDLKGLEVTSVT--------VDGKPLDFTRDGERLTI 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  88 SFPSTLQTG-TGTLKIDFVGELNDKMKGFYRSKYTtpsGEVRYAAVTQFEN--------VIDRkpyPDDE---------- 148
Cdd:COG0308   82 TLPKPLAPGeTFTLEIEYSGKPSNGGEGLYRSGDP---PDGPPYLYTQCEPegarrwfpCFDH---PDDKatftltvtvp 155
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 149 ---------NLVEVK----------FARTPVMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTL 209
Cdd:COG0308  156 agwvavsngNLVSETelgdgrttwhWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRML 235
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 210 PFYKDYFNVPYPLPKIDLIAIADFAAGAMENWGLVTYRETalLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWT 289
Cdd:COG0308  236 DFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEK--VLADETATDADYERRESVIAHELAHQWFGNLVTCADWD 313
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 290 HLWLNEGFASWIEYLCVDHCFPEyDIWTQFVSADYTRAQ-ELDALDNSHPIEVSvgHPSEVDEIFDAISYSKGASVIRML 368
Cdd:COG0308  314 DLWLNEGFATYMEQLFSEDLYGK-DAADRIFVGALRSYAfAEDAGPNAHPIRPD--DYPEIENFFDGIVYEKGALVLHML 390
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 369 HDYIGDKDFKKGMNMYLTKFQQKNAATEDLWESLENASGKPIAAVMNTWTKQMGFPLIYVEAEQVEDDRL-LRLSQKKFc 447
Cdd:COG0308  391 RTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAFFDQWLYQAGLPTLEVEYEYDADGKVtLTLRQTPP- 469
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 448 aggsyvgeDCPQWMVPITISTsEDPNQAKLKILMDKPEMNVVlknVKPDqWVKLNLgtvgfyrtqyssamLESLLPGIRD 527
Cdd:COG0308  470 --------RPHPFHIPLEVGL-LGGKLTARTVLLDGEQTELV---AKPD-PVLLLR--------------LDDELAFLLA 522
                        570       580       590       600       610
                 ....*....|....*....|....*....|....*....|....*....|...
gi 221041544 528 LSLPPVDRLGLQNDLFSLARAGIISTVEVLKvmeafvnEPNYTVWSDLSCNLG 580
Cdd:COG0308  523 HDSDPFNRWEALQALWRDGEADYLDALRALA-------DTDPAVRAEALALLG 568
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
498-811 4.99e-106

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 328.85  E-value: 4.99e-106
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  498 WVKLNLGTVGFYRTQYSSAMLESLLPGIRDLSLPPVDRLGLQNDLFSLARAGIISTVEVLKVMEAFVNEPNYTVWSDLSC 577
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLLSKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAALS 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  578 NLGILSTLLSHTDFYEEIQEFVKDVFSPIGERLGWDPKPGEGHLDALLRGLVLGKLGKAGHKATLEEARRRFKDHVEGKQ 657
Cdd:pfam11838  81 QLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEAPPGESHLDRQLRALLLSAACSAGDPECVAEAKKLFDAWLDGDD 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  658 ILSADLRSPVYLTVLKHGDGTTLDIMLKLHKQADMQEEKNRIERVLGATLLPDLIQKVLTFAL-SEEVRPQDTVSVIGGV 736
Cdd:pfam11838 161 AIPPDLRWAVYCAAVANGGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALdSDEVRNQDLRAVIAGL 240
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 221041544  737 AGgSKHGRKAAWKFIKDNWEELYNRYQGGFLISRLIKLSVEGFAVDKMAGEVKAFFESHPAPSAERTIQQCCENI 811
Cdd:pfam11838 241 AS-NPAGRDLAWDFVKENWDALVKRLGGGSSLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRRALAQALETI 314
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
154-438 1.48e-62

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 226.21  E-value: 1.48e-62
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  154 KFARTPVMSTYLVAFVVGEYDFVETRSkDGVCVRVYTPVGKAEQ--GKFALEVAAKTLPFYKDYFNVPYPLPKIDLIAIA 231
Cdd:TIGR02412 176 EFPETPKLSTYLTAVAAGPYHSVQDES-RSYPLGIYARRSLAQYldADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVP 254
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  232 DFAAGAMENWGLVTYRETALLIDPKNScsSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWIEYLCVDHCfP 311
Cdd:TIGR02412 255 EFNAGAMENAGCVTFAENFLHRAEATR--AEKENRAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASAEA-T 331
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  312 EY-DIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGMNMYLTKFQQ 390
Cdd:TIGR02412 332 EYtDAWTTFAAQGKQWAYEADQLPTTHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAF 411
                         250       260       270       280
                  ....*....|....*....|....*....|....*....|....*...
gi 221041544  391 KNAATEDLWESLENASGKPIAAVMNTWTKQMGFPLIYVEAEqVEDDRL 438
Cdd:TIGR02412 412 GNATLDDLIDSLAKASGRDLSAWSDAWLETAGVNTLTPEIT-TDGGVV 458
pepN PRK14015
aminopeptidase N; Provisional
164-448 1.57e-17

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 87.49  E-value: 1.57e-17
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 164 YLVAFVVGEYDFVE----TRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYplpkiDL-----IAIADFA 234
Cdd:PRK14015 190 YLFALVAGDLDVLEdtftTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKWDEERFGLEY-----DLdifmiVAVDDFN 264
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 235 AGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGfaswieyLCV--DHCFpe 312
Cdd:PRK14015 265 MGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEG-------LTVfrDQEF-- 335
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 313 ydiwtqfvSAD-------------YTRAQEL--DALDNSHPIEvsvghPSEVDEI---FDAISYSKGASVIRMLHDYIGD 374
Cdd:PRK14015 336 --------SADlgsravkriedvrVLRAAQFaeDAGPMAHPVR-----PDSYIEInnfYTATVYEKGAEVIRMLHTLLGE 402
                        250       260       270       280       290       300       310
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 221041544 375 KDFKKGMNMYLTKF--QqknAAT-EDLWESLENASGKPIAAVMNtWTKQMGFPLIYVEAEQVEDDRLLRLSQKKFCA 448
Cdd:PRK14015 403 EGFRKGMDLYFERHdgQ---AVTcEDFVAAMEDASGRDLSQFRR-WYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTP 475
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
17-419 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 608.04  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  17 INYSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASYAPEGDEEIHATGFNYQNEDEKVTLSFPSTLQTG 96
Cdd:cd09601    1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETEFLTITLDETLPPG 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  97 T-GTLKIDFVGELNDKMKGFYRSKYTTPSGEVRYAAVTQFE----------------------------------NVIDR 141
Cdd:cd09601   81 EnYTLSIEFTGKLNDDLRGFYRSSYTDEDGETRYLAATQFEptdarrafpcfdepafkatfditithpkgytalsNMPPV 160
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 142 KPYPDDENLVEVKFARTPVMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYP 221
Cdd:cd09601  161 ESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIPYP 240
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 222 LPKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWI 301
Cdd:cd09601  241 LPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFATYM 320
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 302 EYLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGM 381
Cdd:cd09601  321 EYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVFRKGL 400
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|..
gi 221041544 382 NMYLTKFQQKNAATEDLWESLENASG----KPIAAVMNTWTK 419
Cdd:cd09601  401 RKYLKKHAYGNATTDDLWEALQEASGeskpLDVKEIMDSWTL 442
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
200-417 1.84e-124

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 373.16  E-value: 1.84e-124
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  200 FALEVAAKTLPFYKDYFNVPYPLPKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWF 279
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  280 GNLVTMEWWTHLWLNEGFASWIEYLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYS 359
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*....
gi 221041544  360 KGASVIRMLHDYIGDKDFKKGMNMYLTKFQQKNAATEDLWESLENASG-KPIAAVMNTW 417
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGpLDVDSFMDTW 219
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
9-580 8.84e-115

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 362.04  E-value: 8.84e-115
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544   9 RLPADVSPINYSLCLKPDLLDFTFEGKLEAAAQVRQA-TNQIVMNCADIDIITASyapegdeeIHATGFNYQNEDEKVTL 87
Cdd:COG0308   10 YRPPGYDVTHYDLDLDLDPATTRLSGTATITFTATEApLDSLVLDLKGLEVTSVT--------VDGKPLDFTRDGERLTI 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  88 SFPSTLQTG-TGTLKIDFVGELNDKMKGFYRSKYTtpsGEVRYAAVTQFEN--------VIDRkpyPDDE---------- 148
Cdd:COG0308   82 TLPKPLAPGeTFTLEIEYSGKPSNGGEGLYRSGDP---PDGPPYLYTQCEPegarrwfpCFDH---PDDKatftltvtvp 155
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 149 ---------NLVEVK----------FARTPVMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTL 209
Cdd:COG0308  156 agwvavsngNLVSETelgdgrttwhWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRML 235
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 210 PFYKDYFNVPYPLPKIDLIAIADFAAGAMENWGLVTYRETalLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWT 289
Cdd:COG0308  236 DFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEK--VLADETATDADYERRESVIAHELAHQWFGNLVTCADWD 313
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 290 HLWLNEGFASWIEYLCVDHCFPEyDIWTQFVSADYTRAQ-ELDALDNSHPIEVSvgHPSEVDEIFDAISYSKGASVIRML 368
Cdd:COG0308  314 DLWLNEGFATYMEQLFSEDLYGK-DAADRIFVGALRSYAfAEDAGPNAHPIRPD--DYPEIENFFDGIVYEKGALVLHML 390
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 369 HDYIGDKDFKKGMNMYLTKFQQKNAATEDLWESLENASGKPIAAVMNTWTKQMGFPLIYVEAEQVEDDRL-LRLSQKKFc 447
Cdd:COG0308  391 RTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAFFDQWLYQAGLPTLEVEYEYDADGKVtLTLRQTPP- 469
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 448 aggsyvgeDCPQWMVPITISTsEDPNQAKLKILMDKPEMNVVlknVKPDqWVKLNLgtvgfyrtqyssamLESLLPGIRD 527
Cdd:COG0308  470 --------RPHPFHIPLEVGL-LGGKLTARTVLLDGEQTELV---AKPD-PVLLLR--------------LDDELAFLLA 522
                        570       580       590       600       610
                 ....*....|....*....|....*....|....*....|....*....|...
gi 221041544 528 LSLPPVDRLGLQNDLFSLARAGIISTVEVLKvmeafvnEPNYTVWSDLSCNLG 580
Cdd:COG0308  523 HDSDPFNRWEALQALWRDGEADYLDALRALA-------DTDPAVRAEALALLG 568
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
498-811 4.99e-106

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 328.85  E-value: 4.99e-106
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  498 WVKLNLGTVGFYRTQYSSAMLESLLPGIRDLSLPPVDRLGLQNDLFSLARAGIISTVEVLKVMEAFVNEPNYTVWSDLSC 577
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQLLSKVLSPLDRAGLIDDAFALARAGELSTSDALDLVLAYLNETDYVVWSAALS 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  578 NLGILSTLLSHTDFYEEIQEFVKDVFSPIGERLGWDPKPGEGHLDALLRGLVLGKLGKAGHKATLEEARRRFKDHVEGKQ 657
Cdd:pfam11838  81 QLSTLRSLLSADPEYEALKAFLRKLLSPLAEKLGWEAPPGESHLDRQLRALLLSAACSAGDPECVAEAKKLFDAWLDGDD 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  658 ILSADLRSPVYLTVLKHGDGTTLDIMLKLHKQADMQEEKNRIERVLGATLLPDLIQKVLTFAL-SEEVRPQDTVSVIGGV 736
Cdd:pfam11838 161 AIPPDLRWAVYCAAVANGGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALdSDEVRNQDLRAVIAGL 240
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 221041544  737 AGgSKHGRKAAWKFIKDNWEELYNRYQGGFLISRLIKLSVEGFAVDKMAGEVKAFFESHPAPSAERTIQQCCENI 811
Cdd:pfam11838 241 AS-NPAGRDLAWDFVKENWDALVKRLGGGSSLGRLVKGLTPSFSTEEELDEVEAFFADKDTPGLRRALAQALETI 314
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
146-420 5.26e-87

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 283.25  E-value: 5.26e-87
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 146 DDENLVEVKFARTPVMSTYLVAFVVGEYDFVEtRSKDGVCVRVYTPVGKAEQGKFA---LEVAAKTLPFYKDYFNVPYPL 222
Cdd:cd09602  166 EAGGRKRWRFAETPPLSTYLFAFVAGPYHRVE-DEHDGIPLGLYCRESLAEYERDAdeiFEVTKQGLDFYEDYFGIPYPF 244
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 223 PKIDLIAIADFAAGAMENWGLVTYRETALLIDPKNScsSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWIE 302
Cdd:cd09602  245 GKYDQVFVPEFNFGAMENPGAVTFRESYLFREEPTR--AQRLRRANTILHEMAHMWFGDLVTMKWWDDLWLNESFADFMA 322
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 303 YLCVDHCFPEYDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGMN 382
Cdd:cd09602  323 AKALAEATPFTDAWLTFLLRRKPWAYRADQLPTTHPIAQDVPDLEAAGSNFDGITYAKGASVLKQLVALVGEEAFRAGLR 402
                        250       260       270
                 ....*....|....*....|....*....|....*...
gi 221041544 383 MYLTKFQQKNAATEDLWESLENASGKPIAAvmntWTKQ 420
Cdd:cd09602  403 EYFKKHAYGNATLDDLIAALDEASGRDLSA----WADA 436
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
19-403 2.80e-80

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 264.69  E-value: 2.80e-80
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  19 YSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASYapEGDEEIHATGFNYQNEDEKVTLSFPstlQTGTG 98
Cdd:cd09595    3 YDLDLDVDFTTKTLNGTETLTVDASQVGRELVLDLVGLTIHSVSV--NGAAVDFGEREHYDGEKLTIPGPKP---PGQTF 77
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  99 TLKIDFVGELNDKMKGFYRSKYttpSGEVRYAAVTQFEN-----------------------VIDRKPY----------- 144
Cdd:cd09595   78 TVRISFEAKPSKNLLGWLWEQT---AGKEKPYLFTQFEAtharrifpcidhpavkatftvtiTTPKKDLlasngalvgee 154
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 145 PDDENLVEVKFARTPVMSTYLVAFVVG--EYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYPL 222
Cdd:cd09595  155 TGANGRKTYRFEDTPPIPTYLVAVVVGdlEFKYVTVKSQPRVGLSVYSEPLQVDQAQYAFDATRAALAWFEDYFGGPYPL 234
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 223 PKIDLIAIADFAAGAMENWGLVTYRETALLIDpKNSCSSSRQwVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWIE 302
Cdd:cd09595  235 PKYDLLAVPDFNSGAMENPGLITFRTTYLLRS-KVTDTGARS-IENVIAHELAHQWFGNLVTMRWWNDLWLNEGFAVYYE 312
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 303 YLCVDHCFPEyDIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGMN 382
Cdd:cd09595  313 NRIMDATFGT-SSRHLDQLSGSSDLNTEQLLEDSSPTSTPVRSPADPDVAYDGVTYAKGALVLRMLEELVGEEAFDKGVQ 391
                        410       420
                 ....*....|....*....|.
gi 221041544 383 MYLTKFQQKNAATEDLWESLE 403
Cdd:cd09595  392 AYFNRHKFKNATTDDFIDALE 412
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
154-438 1.48e-62

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 226.21  E-value: 1.48e-62
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  154 KFARTPVMSTYLVAFVVGEYDFVETRSkDGVCVRVYTPVGKAEQ--GKFALEVAAKTLPFYKDYFNVPYPLPKIDLIAIA 231
Cdd:TIGR02412 176 EFPETPKLSTYLTAVAAGPYHSVQDES-RSYPLGIYARRSLAQYldADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVP 254
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  232 DFAAGAMENWGLVTYRETALLIDPKNScsSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGFASWIEYLCVDHCfP 311
Cdd:TIGR02412 255 EFNAGAMENAGCVTFAENFLHRAEATR--AEKENRAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASAEA-T 331
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  312 EY-DIWTQFVSADYTRAQELDALDNSHPIEVSVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDKDFKKGMNMYLTKFQQ 390
Cdd:TIGR02412 332 EYtDAWTTFAAQGKQWAYEADQLPTTHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAF 411
                         250       260       270       280
                  ....*....|....*....|....*....|....*....|....*...
gi 221041544  391 KNAATEDLWESLENASGKPIAAVMNTWTKQMGFPLIYVEAEqVEDDRL 438
Cdd:TIGR02412 412 GNATLDDLIDSLAKASGRDLSAWSDAWLETAGVNTLTPEIT-TDGGVV 458
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
13-417 1.96e-58

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 205.13  E-value: 1.96e-58
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  13 DVspINYSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASYapegdEEIHATGFNYqnEDEKVTLSFPST 92
Cdd:cd09603    2 DV--LHYDLDLDYDPATKSLSGTATITFRATQDLDSLQLDLVGLTVSSVTV-----DGVPAAFFTH--DGDKLVITLPRP 72
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  93 LQTG-TGTLKIDFVGElNDKMKGFYRSKYTTPSGEVRYAAVTQFEN------VIDrkpYPDDENLVEVKF---------- 155
Cdd:cd09603   73 LAAGeTFTVTVRYSGK-PRPAGYPPGDGGGWEEGDDGVWTAGQPEGastwfpCND---HPDDKATYDITVtvpagltvvs 148
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 156 --------------------ARTPvMSTYLVAFVVGEYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDY 215
Cdd:cd09603  149 ngrlvstttngggtttwhwkMDYP-IATYLVTLAVGRYAVVEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFEEL 227
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 216 FnVPYPLPKIDLIAIADFAaGAMENWGLVTYRETALLIDPKnscsssrqWVALVVgHELAHQWFGNLVTMEWWTHLWLNE 295
Cdd:cd09603  228 F-GPYPFEKYGQVVVPDLG-GGMEHQTATTYGNNFLNGDRG--------SERLIA-HELAHQWFGDSVTCADWADIWLNE 296
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 296 GFASWIEYLCVDHCFPEYDiwtqfvsADYTRAQELDALDNSHPIevsVGHPSEVDEIFDAISYSKGASVIRMLHDYIGDK 375
Cdd:cd09603  297 GFATYAEWLWSEHKGGADA-------YRAYLAGQRQDYLNADPG---PGRPPDPDDLFDRDVYQKGALVLHMLRNLLGDE 366
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|..
gi 221041544 376 DFKKGMNMYLTKFQQKNAATEDLWESLENASGKPIAAVMNTW 417
Cdd:cd09603  367 AFFAALRAYLARYAHGNVTTEDFIAAAEEVSGRDLTWFFDQW 408
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
15-165 3.75e-41

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 149.03  E-value: 3.75e-41
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544   15 SPINYSLCLKPDLLDFTFEGKLEAAAQVRQATNQIVMNCADIDIITASY-APEGDEEIHATGFNYQNEDEKVTLSFPSTL 93
Cdd:pfam17900   1 VPEHYDLDLKIDLKNFTFSGSVTITLQLNNATNVIVLHASDLTIRSISLsDEVTSDGVPADFTEDQKDGEKLTIVLPETL 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544   94 -QTGTGTLKIDFVGELNDKMKGFYRSKYTTpSGEVRYAAVTQFE----------------------------------NV 138
Cdd:pfam17900  81 nQTGPYTLEIEYSGELNDSMTGFYRSTYTD-NGEKKVLVTTQFEptdarsafpcfdepsvkatftisiihpkdytalsNM 159
                         170       180
                  ....*....|....*....|....*..
gi 221041544  139 IDRKPYPDDENLVEVKFARTPVMSTYL 165
Cdd:pfam17900 160 PVIASEPLENGWVITTFEQTPKMSTYL 186
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
163-418 6.13e-36

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 141.50  E-value: 6.13e-36
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 163 TYLVAFVVGEYDFVE----TRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYPLPKIDLIAIADFAAGAM 238
Cdd:cd09600  177 SYLFALVAGDLGSVEdtftTKSGRKVKLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDLDLFNIVAVDDFNMGAM 256
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 239 ENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGfaswieyLCV--DHCFPE---- 312
Cdd:cd09600  257 ENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEG-------LTVfrDQEFSAdmns 329
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 313 ------YDI----WTQFVSadytraqelDALDNSHPIEvsvghPSEVDEI---FDAISYSKGASVIRMLHDYIGDKDFKK 379
Cdd:cd09600  330 ravkriEDVrrlrSAQFPE---------DAGPMAHPIR-----PDSYIEInnfYTVTVYEKGAEVIRMLHTLLGEEGFRK 395
                        250       260       270
                 ....*....|....*....|....*....|....*....
gi 221041544 380 GMNMYLTKFQQKNAATEDLWESLENASGKPIAAVMNTWT 418
Cdd:cd09600  396 GMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFKRWYS 434
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
167-417 3.32e-35

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 139.33  E-value: 3.32e-35
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 167 AFVVGEyDF-VETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFnVPYPLPKIDLIAiADFAAGAMENWGLVT 245
Cdd:cd09604  205 AWAASP-DFvVDAATVDGVTVNVYYLPENAEAAERALEYAKDALEFFSEKF-GPYPYPELDVVQ-GPFGGGGMEYPGLVF 281
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 246 yretallIDPKNScsSSRQWVALVVGHELAHQWF----GNLVTMEwwthLWLNEGFASWIEYLCVDHCFPEYDIWTQFVS 321
Cdd:cd09604  282 -------IGSRLY--DPKRSLEGVVVHEIAHQWFygivGNDERRE----PWLDEGLATYAESLYLEEKYGKEAADELLGR 348
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 322 ADYTRAQEldalDNSHPIEVSVGHPSEVDEIFDAIsYSKGASVIRMLHDYIGDKDFKKGMNMYLTKFQQKNAATEDLWES 401
Cdd:cd09604  349 RYYRAYAR----GPGGPINLPLDTFPDGSYYSNAV-YSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRT 423
                        250
                 ....*....|....*.
gi 221041544 402 LENASGKPIAAVMNTW 417
Cdd:cd09604  424 AEEVSGKDLDWFFRGW 439
pepN PRK14015
aminopeptidase N; Provisional
164-448 1.57e-17

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 87.49  E-value: 1.57e-17
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 164 YLVAFVVGEYDFVE----TRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNVPYplpkiDL-----IAIADFA 234
Cdd:PRK14015 190 YLFALVAGDLDVLEdtftTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKWDEERFGLEY-----DLdifmiVAVDDFN 264
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 235 AGAMENWGLVTYRETALLIDPKNSCSSSRQWVALVVGHELAHQWFGNLVTMEWWTHLWLNEGfaswieyLCV--DHCFpe 312
Cdd:PRK14015 265 MGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEG-------LTVfrDQEF-- 335
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 313 ydiwtqfvSAD-------------YTRAQEL--DALDNSHPIEvsvghPSEVDEI---FDAISYSKGASVIRMLHDYIGD 374
Cdd:PRK14015 336 --------SADlgsravkriedvrVLRAAQFaeDAGPMAHPVR-----PDSYIEInnfYTATVYEKGAEVIRMLHTLLGE 402
                        250       260       270       280       290       300       310
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 221041544 375 KDFKKGMNMYLTKF--QqknAAT-EDLWESLENASGKPIAAVMNtWTKQMGFPLIYVEAEQVEDDRLLRLSQKKFCA 448
Cdd:PRK14015 403 EGFRKGMDLYFERHdgQ---AVTcEDFVAAMEDASGRDLSQFRR-WYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTP 475
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
161-417 4.02e-15

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 78.65  E-value: 4.02e-15
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 161 MSTYLVAFVVGEYDFVET--RSkdgvcvRVYTPVGKAEQGK--FA-----LEVAAKTLPfykdyfnvPYPLPKID-LIAI 230
Cdd:cd09599  190 IPSYLIAIAVGDLESREIgpRS------GVWAEPSVVDAAAeeFAdtekfLKAAEKLYG--------PYVWGRYDlLVLP 255
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 231 ADFAAGAMENWGLVTYreTALLIdpknscSSSRQWVALVVgHELAHQWFGNLVTMEWWTHLWLNEGFASWIEYLCVDHCF 310
Cdd:cd09599  256 PSFPYGGMENPCLTFA--TPTLI------AGDRSLVDVIA-HEIAHSWSGNLVTNANWEHFWLNEGFTVYLERRILERLY 326
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 311 -PEYdiwTQFVSA--DYTRAQELDALDNSHP-----IEVSVGHPsevDEIFDAISYSKGASVIRMLHDYIGDKDFKKGMN 382
Cdd:cd09599  327 gEEY---RQFEAIlgWKDLQESIKEFGEDPPytllvPDLKGVDP---DDAFSSVPYEKGFQFLYYLEQLGGREVFDPFLR 400
                        250       260       270       280
                 ....*....|....*....|....*....|....*....|
gi 221041544 383 MYLTKFQQKNAATED----LWESLENASGKPIAAVM-NTW 417
Cdd:cd09599  401 AYFKKFAFQSIDTEDfkdfLLEYFAEDKPEILDKIDwDAW 440
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
11-424 1.63e-14

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 77.51  E-value: 1.63e-14
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544   11 PADVSPINYSLCLKPDLLDFTFEGKLEAAAQVRQA-TNQIVMNCADIDIITASyapegdeeIHATGFNYQNEDEK----- 84
Cdd:TIGR02411   8 YKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDnLNKLVLDTSYLDIQKVT--------INGLPADFAIGERKeplgs 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544   85 -VTLSFPSTLQTGTG-TLKIDFvgELNDKMKG--FYRSKYT-------------------------TPSGEVRYAA---- 131
Cdd:TIGR02411  80 pLTISLPIATSKNDEfVLNISF--STTPKCTAlqWLNPEQTsgkkhpylfsqcqaiharslfpcqdTPSVKSTYTAeves 157
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  132 -VTQFENVIDRKPYPDDENlveVKFARTPV-MSTYLVAFVVGEYDF--VETRSKdgvcvrVYT-PVG-KAEQGKFALEV- 204
Cdd:TIGR02411 158 pLPVLMSGIRDGETSNDPG---KYLFKQKVpIPAYLIAIASGDLASapIGPRST------VYSePEQlEKCQYEFENDTe 228
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  205 ----AAKTLPFykdyfnvPYPLPKIDLIAIAD-FAAGAMENWGLvTYRETALLidpknscSSSRQWVAlVVGHELAHQWF 279
Cdd:TIGR02411 229 kfikTAEDLIF-------PYEWGQYDLLVLPPsFPYGGMENPNL-TFATPTLI-------AGDRSNVD-VIAHELAHSWS 292
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544  280 GNLVTMEWWTHLWLNEGFASWIEYLCVDHCFPEYdiwTQFVSA--DYTRAQE-LDALDNSHPIEVSVGHPSEV--DEIFD 354
Cdd:TIGR02411 293 GNLVTNCSWEHFWLNEGWTVYLERRIIGRLYGEK---TRHFSAliGWGDLQEsVKTLGETPEFTKLVVDLKDNdpDDAFS 369
                         410       420       430       440       450       460       470
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 221041544  355 AISYSKGASVIRMLHDYIGD-KDFKKGMNMYLTKFQQKNAATEDLWESL-ENASGKPIAAVMN-----TWTKQMGFP 424
Cdd:TIGR02411 370 SVPYEKGFNFLFYLEQLLGGpAEFDPFLRHYFKKFAYKSLDTYQFKDALyEYFKDKKKVDKLDavdweTWLYSPGMP 446
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
203-304 2.79e-07

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 49.40  E-value: 2.79e-07
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 203 EVAAKTLPFYKDYFNVPYPLPKIDLI--------AIADFAAGAMENWGLVTY------RETALLIDpknscsssrqwval 268
Cdd:cd09594    2 SYAHETYKYYEELLGRTSFRYPVSPIysllvypaYVEVNAYNAMWIPSTNIFygagilDTLSGTID-------------- 67
                         90       100       110
                 ....*....|....*....|....*....|....*..
gi 221041544 269 VVGHELAHQWFGNLVTMEW-WTHLWLNEGFASWIEYL 304
Cdd:cd09594   68 VLAHELTHAFTGQFSNLMYsWSSGWLNEGISDYFGGL 104
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
166-390 2.81e-05

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 47.61  E-value: 2.81e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 166 VAFVVG-----------EYDFVETRSKDGVCVRVYTPVGKAEQGKFALEVAAKTLPFYKDYFNvPYPLP--KI----DLI 228
Cdd:cd09839  267 IGFAVGpfeivplpefrESEEDDKLGSSAVEVTGFCLPGRLEELRNTCSFLHKAMDFFEEEYG-SYPFSsyKQvfvdDLP 345
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 229 A-IADFAAGAMENwglvtyreTALL-----IDPknsCSSSRQwvALVvgHELAHQWFGNLVTMEWWTHLWLNEGFASWIE 302
Cdd:cd09839  346 EdVSSFASLSICS--------SRLLyppdiIDQ---AYETRR--KLA--HALASQWFGINIIPKTWSDTWLVIGIAGYMT 410
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 221041544 303 YLCVDHCF--PEYDIWTQfvsadyTRAQELDALDNSHPievSVGHPSEV----DEIFDAISYsKGASVIRMLHDYIGDKD 376
Cdd:cd09839  411 GLFLKKLFgnNEYRFRIK------KDADRVCELDIGRP---PLAQPGFIlpldPSELEFMAL-KAPLVLFILDRRLTKTG 480
                        250
                 ....*....|....*
gi 221041544 377 FKKGMNMYLTK-FQQ 390
Cdd:cd09839  481 GSFGLSRVLPKiFLQ 495
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH